Publications by authors named "Kimmo Porkka"

92Publications

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.

Leukemia 2020 Nov 9. Epub 2020 Nov 9.

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-01082-4DOI Listing
November 2020

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

N Engl J Med 2020 08;383(7):617-629

From the Department of Leukemia, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., M.K.); the Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento (B.A.J.), the Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte (V. Pullarkat), and Genentech, South San Francisco (W.-J.H.) - all in California; the Section of Hematology and Oncology, Department of Medicine, University of Chicago Medicine, Chicago (M.J.T.), and AbbVie, North Chicago (Y.Z., J.P.) - both in Illinois; the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston (J.S.G., A.L.); the Australian Centre for Blood Diseases, Alfred Hospital and Monash University, Melbourne, VIC (A.H.W.); the Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany (H.D.); Hôpital St. Louis, Assistance Publique-Hôpitaux de Paris and Université de Paris, Paris (P.F.); the Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna (E.K.); the Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels (V.H.); the Department of Medicine, McMaster University, Hamilton, ON, Canada (B.L.); the Department of Hematology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, Barcelona (J.E.); the Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China (J.W.); the Department of Hematology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia (V. Pejsa); the Department of Clinic Subjects, University Hospital Ostrava-Poruba, Ostrava, Czech Republic (R.H.); Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki (K.P.); the Faculty of Medicine, Department of Hematology, University of Debrecen, Debrecen, Hungary (A.I.); Hadassah Medical Center, Jerusalem (D.L.); the Clinic of Hematology, Department of Internal Medicine, University of Genoa, and San Martino Hospital IRCCS - both in Genoa, Italy (R.M.L.); the Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan (K.Y.); the Department of Internal Medicine, Seoul National University College of Medicine (S.-S.Y.), and the Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine (J.-H.J.) - both in Seoul, South Korea; the Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan (S.-P.Y.); the Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Ondokuz Mayıs University, Samsun, Turkey (M.T.); and Abramson Cancer Center, University of Pennsylvania, Philadelphia (K.W.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2012971DOI Listing
August 2020

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.

Leukemia 2020 10 17;34(10):2780-2784. Epub 2020 Jul 17.

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0978-7DOI Listing
October 2020

Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.

Leukemia 2020 Dec 10;34(12):3186-3196. Epub 2020 Jul 10.

Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0972-0DOI Listing
December 2020

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.

Leukemia 2019 10 7;33(10):2548-2553. Epub 2019 Jun 7.

Institute for Molecular Medicine Finland, FIMM, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0504-yDOI Listing
October 2019

Dasatinib and navitoclax act synergistically to target NUP98-NSD1/FLT3-ITD acute myeloid leukemia.

Leukemia 2019 06 19;33(6):1360-1372. Epub 2018 Dec 19.

Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0327-2DOI Listing
June 2019

Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment.

J Pediatr Hematol Oncol 2019 10;41(7):e481-e483

Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001267DOI Listing
October 2019

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.

Leukemia 2018 07 20;32(7):1643-1656. Epub 2018 Jun 20.

Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0175-0DOI Listing
July 2018

Germline alterations in a consecutive series of acute myeloid leukemia.

Leukemia 2018 10 10;32(10):2282-2285. Epub 2018 Apr 10.

Genome-Scale Biology/Research Programs Unit, and Department of Medical and Clinical Genetics/Medicum, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0049-5DOI Listing
October 2018

Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.

Leuk Lymphoma 2018 12 4;59(12):3002-3005. Epub 2018 Apr 4.

a Institute for Molecular Medicine Finland, FIMM, University of Helsinki , Helsinki , Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1453067DOI Listing
December 2018

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.

Leuk Lymphoma 2018 03 4;59(3):725-732. Epub 2017 Aug 4.

a Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science , University of Helsinki , Helsinki , Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1357174DOI Listing
March 2018

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

PLoS One 2017 30;12(1):e0171041. Epub 2017 Jan 30.

Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171041PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279791PMC
August 2017

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.

Cancer Immunol Res 2017 02 10;5(2):157-169. Epub 2017 Jan 10.

Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-16-0061-TDOI Listing
February 2017

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.

J Clin Oncol 2017 Jan 7;35(2):175-184. Epub 2016 Nov 7.

Sieghart Sopper, Günther Gastl, Matthias Baldauf, Zlatko Trajanoski, and Dominik Wolf, Medical University Innsbruck; Sieghart Sopper and Dominik Wolf, Tyrolean Cancer Research Institute; Matthias Baldauf, Oncotyrol, Innsbruck; Peter Valent, Medical University of Vienna, Vienna, Austria; Satu Mustjoki and Kimmo Porkka, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; Deborah White and Timothy Hughes, South Australian Health and Medical Research Institute and University of Adelaide School of Medicine, Adelaide, South Australia, Australia; Andreas Burchert, Universitätsklinikum Gießen und Marburg and Philipps Universität Marburg, Marburg; Andreas Hochhaus, Thomas Ernst, and Thomas Schenk, Universitätsklinikum Jena, Jena; Dominik Wolf, University Hospital of Bonn, Bonn, Germany; Bjørn T. Gjertsen, University of Bergen, Bergen, Norway; Frank Giles, Northwestern University, Chicago, IL; and Jeroen J.W.M. Janssen and Gert J. Ossenkoppele, Vrije Universiteit Medical Center, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.0893DOI Listing
January 2017

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Clin Cancer Res 2016 Aug 22;22(16):4030-8. Epub 2016 Mar 22.

Hematology Research Unit Helsinki, University of Helsinki and Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2791DOI Listing
August 2016

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

J Cancer Res Clin Oncol 2016 May 8;142(5):1041-50. Epub 2016 Jan 8.

Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, Haartmaninkatu 8, P.O. Box 700, 00290, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-015-2101-4DOI Listing
May 2016

Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians.

Patient Prefer Adherence 2014 24;8:1619-27. Epub 2014 Nov 24.

Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PPA.S70712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246993PMC
December 2014

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells.

Oncoimmunology 2014 29;3:e28925. Epub 2014 May 29.

Hematology Research Unit Helsinki; University of Helsinki; Helsinki, Finland ; Department of Hematology; Helsinki University Central Hospital Cancer Center; Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.28925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106168PMC
May 2014

Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations.

Ann Med 2014 May 11;46(3):114-22. Epub 2014 Feb 11.

Hematology Research Unit, Department of Medicine, University of Helsinki and Helsinki University Central Hospital , Helsinki , Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/07853890.2014.882105DOI Listing
May 2014

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.

PLoS One 2014 31;9(1):e87794. Epub 2014 Jan 31.

Hematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087794PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909235PMC
October 2014

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Eur J Haematol 2014 28;92(5):413-20. Epub 2014 Jan 28.

Hematology Research Unit Helsinki, Department of Medicine, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.12258
Publisher Site
http://dx.doi.org/10.1111/ejh.12258DOI Listing
December 2014

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Cancer Discov 2013 Dec 20;3(12):1416-29. Epub 2013 Sep 20.

1Institute for Molecular Medicine Finland, FIMM; 2Hematology Research Unit Helsinki, Helsinki University Central Hospital, University of Helsinki, Helsinki; 3Department of Clinical Chemistry and TYKSLAB, Turku University Central Hospital, University of Turku, Turku; 4Department of Internal Medicine, Tampere University Hospital, Tampere, Finland; 5Department of Clinical Science, Hematology Section, University of Bergen; and 6Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0350DOI Listing
December 2013

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy.

Leuk Lymphoma 2014 Apr 25;55(4):934-7. Epub 2013 Jul 25.

Hematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital , Helsinki , Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.812788DOI Listing
April 2014

Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients.

Exp Hematol 2012 Sep 1;40(9):705-714.e3. Epub 2012 Jun 1.

Hematology Research Unit Helsinki, Department of Medicine, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2012.05.010DOI Listing
September 2012

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.

Leuk Lymphoma 2012 Dec 18;53(12):2351-61. Epub 2012 Jun 18.

Department of Hematology and Advanced Oncohematologic Therapies Group IIS-IP, Hospital Universitario de La Princesa, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.695779DOI Listing
December 2012

[Current therapy of chronic myeloid leukemia].

Duodecim 2012 ;128(6):579-88

Hematologinen tutkimusyksikkö (HruH), HYKS: n hematologian klinikka.

View Article

Download full-text PDF

Source
May 2012

Interferon alpha for treatment of chronic myeloid leukemia.

Curr Drug Targets 2011 Mar;12(3):420-8

Department of Hematology, University of Uppsala, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011794815301DOI Listing
March 2011

Second-generation BCR-ABL kinase inhibitors in CML.

N Engl J Med 2010 10;363(17):1673; author reply 1673-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1007927DOI Listing
October 2010

Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.

Exp Hematol 2011 Jan 12;39(1):102-113.e1. Epub 2010 Oct 12.

Hematology Research Unit, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2010.09.005DOI Listing
January 2011

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.

Eur J Haematol 2010 Nov;85(5):387-98

Biomedicum Helsinki, Helsinki University Central Hospital, Finland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1600-0609.2010.01501.x
Publisher Site
http://dx.doi.org/10.1111/j.1600-0609.2010.01501.xDOI Listing
November 2010

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Br J Haematol 2009 Jun 15;145(5):581-97. Epub 2009 Apr 15.

Department of Pharmacology, University of Tromso, Tromso, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07666.xDOI Listing
June 2009

Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.

Expert Rev Hematol 2009 Feb;2(1):81-91

Department of Medicine (Division of Hematology), Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2.1.81DOI Listing
February 2009

[Not Available].

Duodecim 2006 ;122(18):2259-66

Haartman-instituutti, virologian osasto, Helsingin yliopisto.

View Article

Download full-text PDF

Source
April 2008

Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells.

Pediatr Blood Cancer 2007 Apr;48(4):387-92

Molecular/Cancer Biology Laboratory, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pbc.20857
Publisher Site
http://dx.doi.org/10.1002/pbc.20857DOI Listing
April 2007

[Stem cell transplantation].

Authors:
Kimmo Porkka

Duodecim 2004 ;120(11):1391-9

HYKS:n hematologian klinikka.

View Article

Download full-text PDF

Source
January 2005

[Developments in blood transfusion].

Duodecim 2004 ;120(7):857-9

SPR Veripalvelu Kivihaantie 7 00310 Helsinki.

View Article

Download full-text PDF

Source
October 2004

Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.

Cancer Cell 2003 Nov;4(5):383-91

Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1535-6108(03)00273-3DOI Listing
November 2003

[The odd omes and omics].

Duodecim 2002 ;118(11):1193-5

View Article

Download full-text PDF

Source
November 2002

[Ligandomics--a tool for the development of targeted treatments].

Duodecim 2002 ;118(11):1185-92

HUS, sisätautien toimiala, hematologian klinikka.

View Article

Download full-text PDF

Source
November 2002

[The "omics" are coming--one gene is not enough anymore].

Duodecim 2002 ;118(11):1146-8

Haartman-instituutti ja HYKS-laboratoriodiagnostiikka Biomedicum Helsinki 00014 Helsingin yliopisto.

View Article

Download full-text PDF

Source
November 2002

A tumor-homing peptide with a targeting specificity related to lymphatic vessels.

Nat Med 2002 Jul 10;8(7):751-5. Epub 2002 Jun 10.

Cancer Research Center, The Burnham Institute, La Jolla, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm720DOI Listing
July 2002

A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo.

Proc Natl Acad Sci U S A 2002 May;99(11):7444-9

Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.062189599DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC124250PMC
May 2002